Characterization of Cardiac Progenitors Derived from 22q11-deleted Patients

22q11 缺失患者心脏祖细胞的表征

• 批准号: 7818254
• 负责人: KENNETH R CHIEN
• 金额: $ 50万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7818254
• 关键词: 22q11; Animal Model; Biological Models; Candidate Disease Gene; Cardiac; Cardiac Myocytes; Cell Differentiation process; Cell Line; Cells; Clinical Data; DNA; Data; Development; Family member; Fibroblasts; Gene Dosage; Gene Expression; Gene Expression Profile; Gene Mutation; Genetic; Genetic Transcription; Genomics; Heart; Heritability; Human; Individual; Infant; Lead; Left ventricular structure; Lesion; Link; Measures; Mesenchymal; Modeling; Molecular Profiling; Morbidity - disease rate; Morphogenesis; Multipotent Stem Cells; Mutation; Myocardial; Parents; Pathogenesis; Patients; Pattern; Phenotype; Pluripotent Stem Cells; Population; Population Study; Positioning Attribute; Production; RNA; RNA Sequences; RNA Splicing; Registries; Resources; Right ventricular structure; Sampling; Skin; Smooth Muscle; Somatic Cell; Stem cells; Structure; Study models; System; Testing; Tetralogy of Fallot; Time; cardiogenesis; clinical phenotype; congenital heart disorder; improved; in vitro Model; induced pluripotent stem cell; insight; malformation; microdeletion; molecular phenotype; mortality; novel; progenitor; public health relevance; repository; research study; stem; transcription factor

DESCRIPTION (provided by applicant): A fundamental limitation in understanding the pathogenesis of congenital heart disease has been the lack of model systems to study human heart development. Studies in model organisms have been informative, but clearly interspecies differences exist that importantly influence the effects of gene mutations on heart development. Recent advances have established model in vitro systems of human heart differentiation from pluripotent stem cells, and have permitted development of pluripotent stem cells from somatic cells of congenital heart disease patients. Collectively, these advances position us to study for the first time the effect of gene mutations on human heart development. Multipotent progenitors in the second heart field (SHF), marked by expression of the transcription factor ISL1, contribute to cardiomyocyte, smooth muscle, and endothelial, lineages of the right ventricle and outflow tract. Deletion of 22q11, the most common chromosomal microdeletion, causes congenital heart disease characterized by abnormalities of right ventricle and outflow tract development, at least in part as a result of reduced gene dosage of TBX1, a key transcriptional regulator of SHF differentiation. Growing evidence suggests that 22q11 deletion causes congenital heart disease by disrupting differentiation of SHF progenitors. However, this hypothesis has not been directly studied, particularly in SHF progenitors derived from human patients. In this proposal, we directly test this hypothesis using induced-pluripotent (iPS) cells derived from 22q11-deleted patients with tetralogy of Fallot (TOF). First, we will generate a repository of TOF fibroblasts and parental controls. We will select 22q11-deleted fibroblasts and non-deleted parental controls, and generate iPS cell lines. Second, we will characterize the differentiation of 22q11-deleted versus control SHF progenitors. Third, we will use whole transcriptome sequencing (RNA-seq) to characterize the transcriptome of 22q11-deleted versus control SHF progenitors. These experiments will link a defined genetic alteration (22q11 deletion) with patient-specific cellular phenotypes and molecular alterations in gene transcription. The results will lead to novel insights on the pathogenesis of TOF as a result of 22q11 deletion, and will establish a model for studying the pathogenesis of other forms of congenital heart disease. Public Health Relevance: Congenital heart disease is the leading non-infectious cause of morbidity and mortality among infants. Over the past two decades, studies in model organisms have greatly advanced our understanding of the genetic causes of congenital heart disease. However, it has not been possible to directly study the effect of gene mutations on human heart development. Recent advances in production of pluripotent cells from skin cells of patients allows us for the first time to overcome this hurdle and directly investigate the effect of gene mutations on human heart development. In this proposal, we study the effect of 22q11 deletion, the most common chromosomal microdeletion associated with congenital heart disease, on cardiac differentiation and gene expression in progenitor cells derived from patients with 22q11 deletion and tetralogy of Fallot. These studies will yield unique insights into how 22q11 deletion causes this form of congenital heart disease.

描述(由申请人提供)：在理解先天性心脏病发病机制方面的一个基本限制是缺乏研究人类心脏发育的模型系统。在模式生物中的研究提供了信息，但显然存在物种间的差异，这些差异对基因突变对心脏发育的影响非常重要。最近的进展已经建立了人类心脏多能干细胞分化的体外模型系统，并允许从先天性心脏病患者的体细胞中开发出多能干细胞。总而言之，这些进展使我们能够首次研究基因突变对人类心脏发育的影响。以转录因子Isl1的表达为标志的第二心区(SHF)中的多能祖细胞对心肌细胞、平滑肌和内皮细胞、右心室和流出道的谱系做出贡献。22q11是最常见的染色体微缺失，它的缺失会导致以右室和流出道发育异常为特征的先天性心脏病，至少部分原因是SHF分化的关键转录调节因子TBX1的基因剂量减少。越来越多的证据表明，22q11缺失通过扰乱SHF祖细胞的分化而导致先天性心脏病。然而，这一假说还没有被直接研究，特别是在来自人类患者的SHF祖细胞中。在这项建议中，我们直接使用来自22q11缺失的法洛四联症(TOF)患者的诱导多能(IPS)细胞来验证这一假设。首先，我们将建立TOF成纤维细胞和父母对照的资料库。我们将选择22q11缺失的成纤维细胞和未缺失的亲本对照，并建立iPS细胞系。其次，我们将鉴定22q11缺失的SHF前体细胞与对照SHF前体细胞的分化。第三，我们将使用完整的转录组测序(RNA-seq)来表征22q11缺失的SHF祖细胞和对照SHF前体的转录组。这些实验将把明确的基因改变(22q11缺失)与患者特定的细胞表型和基因转录中的分子改变联系起来。这一结果将对22q11缺失引起的TOF的发病机制有新的认识，并将为研究其他形式的先天性心脏病的发病机制建立一个模型。 公共卫生相关性：先天性心脏病是婴儿发病率和死亡率的主要非传染性原因。在过去的二十年里，对模式生物的研究极大地促进了我们对先天性心脏病遗传原因的理解。然而，还不可能直接研究基因突变对人类心脏发育的影响。从患者的皮肤细胞中生产多能细胞的最新进展使我们第一次能够克服这一障碍，并直接研究基因突变对人类心脏发育的影响。在这项研究中，我们研究了与先天性心脏病相关的最常见的染色体微缺失22q11缺失对心脏分化和来自22q11缺失和法洛四联症患者祖细胞基因表达的影响。这些研究将对22q11缺失如何导致这种形式的先天性心脏病产生独特的见解。